Eosinophilic Asthma: Pathophysiology and Therapeutic Horizons

Overview

Journal Cells

Publisher MDPI

Specialties Biochemistry
Biophysics
Cell Biology
Molecular Biology

Date 2024 Mar 13

PMID 38474348

Authors

Musaddique Hussain

Gang Liu

Affiliations

Soon will be listed here.

Abstract

Asthma is a prevalent chronic non-communicable disease, affecting approximately 300 million people worldwide. It is characterized by significant airway inflammation, hyperresponsiveness, obstruction, and remodeling. Eosinophilic asthma, a subtype of asthma, involves the accumulation of eosinophils in the airways. These eosinophils release mediators and cytokines, contributing to severe airway inflammation and tissue damage. Emerging evidence suggests that targeting eosinophils could reduce airway remodeling and slow the progression of asthma. To achieve this, it is essential to understand the immunopathology of asthma, identify specific eosinophil-associated biomarkers, and categorize patients more accurately based on the clinical characteristics (phenotypes) and underlying pathobiological mechanisms (endotypes). This review delves into the role of eosinophils in exacerbating severe asthma, exploring various phenotypes and endotypes, as well as biomarkers. It also examines the current and emerging biological agents that target eosinophils in eosinophilic asthma. By focusing on these aspects, both researchers and clinicians can advance the development of targeted therapies to combat eosinophilic pathology in severe asthma.

Citing Articles

Aurantio-Obtusin Suppresses Airway Inflammation and Serum ICAM-1 Expression in Guinea Pig Allergic Asthma Model.

Nyarko M, Danquah C, Antwi A, Emikpe B, Osafo N Immun Inflamm Dis. 2025; 13(3):e70160.

PMID: 40019000 PMC: 11868993. DOI: 10.1002/iid3.70160.

Eosinophil-Driven vs. Eosinophil-Associated Severe Asthma: Practical Implications for Target Treatment.

DAiuto V, Mormile I, Granata F, Romano A, Della Casa F, Mignogna G Int J Mol Sci. 2025; 26(4).

PMID: 40004192 PMC: 11855446. DOI: 10.3390/ijms26041729.

Exploring Asthma as a Protective Factor in COVID-19 Outcomes.

Quinn A, Zhao L, Bell S, Huq M, Fang Y Int J Mol Sci. 2025; 26(4).

PMID: 40004141 PMC: 11855143. DOI: 10.3390/ijms26041678.

Angiogenesis Factors as Emerging Circulating Biomarkers in Asthma.

Lee P, An M, Jang A Allergy Asthma Immunol Res. 2025; 17(1):22-31.

PMID: 39895600 PMC: 11791373. DOI: 10.4168/aair.2025.17.1.22.

Pyroptosis in asthma: inflammatory phenotypes, immune and non-immune cells, and novel treatment approaches.

Hao Y, Wang W, Zhang L, Li W Front Pharmacol. 2024; 15:1452845.

PMID: 39611173 PMC: 11603363. DOI: 10.3389/fphar.2024.1452845.

References

Kuruvilla M, Lee F, Lee G . Understanding Asthma Phenotypes, Endotypes, and Mechanisms of Disease. Clin Rev Allergy Immunol. 2018; 56(2):219-233. PMC: 6411459. DOI: 10.1007/s12016-018-8712-1. View

Nussbaum J, Van Dyken S, von Moltke J, Cheng L, Mohapatra A, Molofsky A . Type 2 innate lymphoid cells control eosinophil homeostasis. Nature. 2013; 502(7470):245-8. PMC: 3795960. DOI: 10.1038/nature12526. View

Jang Y, Choi J, Jin M, Choi Y, Ryoo Z, Lee H . House Dust Mite Increases pro-Th2 Cytokines IL-25 and IL-33 via the Activation of TLR1/6 Signaling. J Invest Dermatol. 2017; 137(11):2354-2361. DOI: 10.1016/j.jid.2017.03.042. View

Ilmarinen P, Hasala H, Sareila O, Moilanen E, Kankaanranta H . Bacterial DNA delays human eosinophil apoptosis. Pulm Pharmacol Ther. 2008; 22(3):167-76. DOI: 10.1016/j.pupt.2008.11.012. View

Khatri S, Moore W, Gibson P, Leigh R, Bourdin A, Maspero J . Assessment of the long-term safety of mepolizumab and durability of clinical response in patients with severe eosinophilic asthma. J Allergy Clin Immunol. 2018; 143(5):1742-1751.e7. DOI: 10.1016/j.jaci.2018.09.033. View

Ujino M, Sugimoto N, Koizumi Y, Ro S, Kojima Y, Asae K . Leukotriene receptor antagonist attenuated airway inflammation and hyperresponsiveness in a double-stranded RNA-induced asthma exacerbation model. Allergol Int. 2017; 66S:S21-S26. DOI: 10.1016/j.alit.2017.05.004. View

Sanz M, Parra A, Prieto I, Dieguez I, Oehling A . Serum eosinophil peroxidase (EPO) levels in asthmatic patients. Allergy. 1997; 52(4):417-22. DOI: 10.1111/j.1398-9995.1997.tb01021.x. View

Guillet C, Steinmann S, Lang C, Maul J, Schmid-Grendelmeier P . Eosinophil-mast cell interaction: Mepolizumab leads to a reduction of clinical symptoms and serum tryptase in a patient with eosinophilic asthma and idiopathic mast cell activation. J Allergy Clin Immunol Pract. 2020; 9(3):1393-1395.e1. DOI: 10.1016/j.jaip.2020.10.020. View

Kankaanranta H, Lahdensuo A, Moilanen E, Barnes P . Add-on therapy options in asthma not adequately controlled by inhaled corticosteroids: a comprehensive review. Respir Res. 2004; 5:17. PMC: 528858. DOI: 10.1186/1465-9921-5-17. View

10.

Tiotiu A . Biomarkers in asthma: state of the art. Asthma Res Pract. 2019; 4:10. PMC: 6302401. DOI: 10.1186/s40733-018-0047-4. View

11.

Murphy K, Jacobs J, Bjermer L, Fahrenholz J, Shalit Y, Garin M . Long-term Safety and Efficacy of Reslizumab in Patients with Eosinophilic Asthma. J Allergy Clin Immunol Pract. 2017; 5(6):1572-1581.e3. DOI: 10.1016/j.jaip.2017.08.024. View

12.

Krug N, Hohlfeld J, Kirsten A, Kornmann O, Beeh K, Kappeler D . Allergen-induced asthmatic responses modified by a GATA3-specific DNAzyme. N Engl J Med. 2015; 372(21):1987-95. DOI: 10.1056/NEJMoa1411776. View

13.

Nair P, Wenzel S, Rabe K, Bourdin A, Lugogo N, Kuna P . Oral Glucocorticoid-Sparing Effect of Benralizumab in Severe Asthma. N Engl J Med. 2017; 376(25):2448-2458. DOI: 10.1056/NEJMoa1703501. View

14.

Shinkai M, Ebisawa M, Fukushima Y, Takeuchi S, Okada H, Tokiyo T . One-year safety and tolerability of tezepelumab in Japanese patients with severe uncontrolled asthma: results of the NOZOMI study. J Asthma. 2022; 60(3):616-624. DOI: 10.1080/02770903.2022.2082309. View

15.

Castro M, Mathur S, Hargreave F, Boulet L, Xie F, Young J . Reslizumab for poorly controlled, eosinophilic asthma: a randomized, placebo-controlled study. Am J Respir Crit Care Med. 2011; 184(10):1125-32. DOI: 10.1164/rccm.201103-0396OC. View

16.

Loureiro C, Duarte I, Gomes J, Carrola J, Barros A, Gil A . Urinary metabolomic changes as a predictive biomarker of asthma exacerbation. J Allergy Clin Immunol. 2013; 133(1):261-3.e1-5. DOI: 10.1016/j.jaci.2013.11.004. View

17.

Castro M, Wenzel S, Bleecker E, Pizzichini E, Kuna P, Busse W . Benralizumab, an anti-interleukin 5 receptor α monoclonal antibody, versus placebo for uncontrolled eosinophilic asthma: a phase 2b randomised dose-ranging study. Lancet Respir Med. 2014; 2(11):879-890. DOI: 10.1016/S2213-2600(14)70201-2. View

18.

Djukanovic R, Wilson S, Kraft M, Jarjour N, Steel M, Chung K . Effects of treatment with anti-immunoglobulin E antibody omalizumab on airway inflammation in allergic asthma. Am J Respir Crit Care Med. 2004; 170(6):583-93. DOI: 10.1164/rccm.200312-1651OC. View

19.

Baraldi E, Carraro S, Alinovi R, Pesci A, Ghiro L, Bodini A . Cysteinyl leukotrienes and 8-isoprostane in exhaled breath condensate of children with asthma exacerbations. Thorax. 2003; 58(6):505-9. PMC: 1746712. DOI: 10.1136/thorax.58.6.505. View

20.

Korhonen R, Moilanen E . Mitogen-activated protein kinase phosphatase 1 as an inflammatory factor and drug target. Basic Clin Pharmacol Toxicol. 2013; 114(1):24-36. DOI: 10.1111/bcpt.12141. View